Bill Cure Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 31-12-2024
- Paid Up Capital ₹ 0.10 M
as on 31-12-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 100.39%
(FY 2022)
- Profit 87.51%
(FY 2022)
- Ebitda -668.50%
(FY 2022)
- Net Worth 9.82%
(FY 2022)
- Total Assets 25.14%
(FY 2022)
About Bill Cure Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manu Sharma and Vikas Sharma serve as directors at the Company.
- CIN/LLPIN
U51397HP2014PTC000701
- Company No.
000701
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bill Cure Pharma Private Limited offer?
Bill Cure Pharma Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antibacterial Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Juices, Soups & Soft Drinks.
Who are the key members and board of directors at Bill Cure Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manu Sharma  | Director | 30-May-2014 | Current |
| Vikas Sharma | Director | 30-May-2014 | Current |
Financial Performance of Bill Cure Pharma.
Bill Cure Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 100.39% increase. The company also saw a substantial improvement in profitability, with a 87.51% increase in profit. The company's net worth moved up by a moderate rise of 9.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bill Cure Pharma?
In 2019, Bill Cure Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bill Cure Pharma?
Unlock and access historical data on people associated with Bill Cure Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bill Cure Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bill Cure Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
